Predictors of ICU Admission and Mechanical Ventilation in Neuroleptic Malignant Syndrome and Malignant Catatonia Presenting to the Emergency Department: A Systematic Review
DOI:
https://doi.org/10.65759/cq89hn42Keywords:
Neuroleptic malignant syndrome, malignant catatonia, emergency department, intensive care unit, mechanical ventilationAbstract
Background. Neuroleptic malignant syndrome and malignant catatonia are uncommon emergencies in which altered consciousness, autonomic instability, and respiratory deterioration complicate disposition, in this systematic review study we aimed to identify factors measured during emergency department assessment that were associated with intensive care unit admission or invasive mechanical ventilation. Methods. PubMed and supplementary searches identified original reports published through 31 May 2026. Reports describing at least two affected patients were eligible when they documented intensive care admission, endotracheal intubation, or mechanical ventilation during the index illness. Findings were synthesized narratively by syndrome, recruitment setting, and outcome. Results. Fifteen original reports contributed data. In a Japanese inpatient cohort of 1,585 patients with neuroleptic malignant syndrome, 408 entered intensive care and 193 underwent intubation. Intensive care admission occurred in 31.4% of typical antipsychotic users and 21.0% of atypical antipsychotic users in a matched inpatient comparison. An Australian adverse-event study showed the opposite numerical pattern. In a treatment-selected series of eight patients with malignant catatonia associated with autoimmune encephalitis, seven received intensive care and four required mechanical ventilation. Conclusions. The evidence describes critical care use and provides limited inpatient associations. Prospective emergency department cohorts with timed baseline measurements and explicit indications for intubation are needed.
References
1. Wijdicks EFM, Ropper AH. Neuroleptic malignant syndrome. N Engl J Med. 2024;391(12):1130–1138. doi:10.1056/NEJMra2404606
2. Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72(9):1222–1228. doi:10.4088/JCP.10m06438
3. Rogers JP, Oldham MA, Fricchione G, Northoff G, Ellen Wilson J, Mann SC, et al. Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2023;37(4):327–369. doi:10.1177/02698811231158232
4. Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry. 1989;146(3):324–328. doi:10.1176/ajp.146.3.324
5. Wilson MP, Vilke GM, Hayden SR, Nordstrom K. Psychiatric emergencies for clinicians: emergency department management of neuroleptic malignant syndrome. J Emerg Med. 2016;51(1):66–69. doi:10.1016/j.jemermed.2015.10.042
6. Connell J, Oldham M, Pandharipande P, Dittus RS, Wilson A, Mart M, et al. Malignant catatonia: a review for the intensivist. J Intensive Care Med. 2023;38(2):137–150. doi:10.1177/08850666221114303
7. Zaman H, Gibson RC, Walcott G. Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. Cochrane Database Syst Rev. 2019;8:CD006570. doi:10.1002/14651858.CD006570.pub3
8. Nakamura M, Yasunaga H, Miyata H, Shimada T, Horiguchi H, Matsuda S. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry. 2012;73(4):427–430. doi:10.4088/JCP.10m06791
9. Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry. 2012;201(1):52–56. doi:10.1192/bjp.bp.111.105189
10. Akın Şen İ, Kılınç M, Şen C, Sungurtekin H. Neuroleptic malignant syndrome requires intensive care monitoring: a review with three cases. Turk J Intensive Care. 2021;19(2):94–97. doi:10.4274/tybd.galenos.2021.18480
11. Paul G, Singhal S, Paul BS, Singh G, Goyal S. Widening spectrum of neuroleptic malignant syndrome: case series. J Anaesthesiol Clin Pharmacol. 2022;38(2):309–314. doi:10.4103/joacp.JOACP_8_21
12. Özdemir F, Birtane D, Yılmaz N, Çukurova Z. Intensive care management and outcomes of neuroleptic malignant syndrome: a single-center retrospective study. Medicina (Kaunas). 2026;62(2):378. doi:10.3390/medicina62020378
13. Touzani S, Hamdouni M, Houari N, Yaakoubi Khbiza Y, Elbouazzaoui A, Boukatta B, et al. Neuroleptic malignant syndrome cases in a Moroccan intensive care unit: a retrospective analysis and literature review. J Neurocrit Care. 2021;14(2):88–97. doi:10.18700/jnc.210019
14. Lopez O, Rabinstein AA, Wijdicks EFM. Contemporary perspectives in critical care of neuroleptic malignant syndrome. Neurocrit Care. 2025;42(3):1018–1024. doi:10.1007/s12028-024-02192-y
15. Pewloungsawat P, Srisuma S, Ruangritchankul S. Clinical outcomes and factors associated with neuroleptic malignant syndrome in older patients: a case control study. J Clin Med. 2025;14(24):8901. doi:10.3390/jcm14248901
16. Chodorowski Z, Anand JS, Rutkowski P. [Neuroleptic malignant syndrome]. Przegl Lek. 2003;60(4):299–301. PubMed
17. Kleinknecht D, Parent A, Blot P, Bochereau G, Lallement PY, Pourriat JL. [Rhabdomyolysis with acute renal failure and malignant neuroleptic syndrome]. Ann Med Interne (Paris). 1982;133(8):549–552. PubMed
18. Isik AT, Kaya D, Ontan MS, Mutlay F, Bulut EA, Dost FS, et al. Neuroleptic malignant syndrome in patients with dementia: experiences of a single memory clinic. Clin Neuropharmacol. 2023;46(6):209–213. doi:10.1097/WNF.0000000000000570
19. Costa M, Covas AR, Correia FN, Bernardo S, Silveira P. Neuroleptic malignant syndrome requiring intensive care unit admission in two patients with SARS-CoV-2 infection in Portugal. Acute Crit Care. 2025;40(2):354–356. doi:10.4266/acc.004632
20. Dessens FM, van Paassen J, van Westerloo DJ, van der Wee NJ, van Vliet IM, van Noorden MS. Electroconvulsive therapy in the intensive care unit for the treatment of catatonia: a case series and review of the literature. Gen Hosp Psychiatry. 2016;38:37–41. doi:10.1016/j.genhosppsych.2015.09.008
21. Park J, Tan J, Krzeminski S, Hazeghazam M, Bandlamuri M, Carlson RW. Malignant catatonia warrants early psychiatric-critical care collaborative management: two cases and literature review. Case Rep Crit Care. 2017;2017:1951965. doi:10.1155/2017/1951965
22. Kraiter FG, May DT, Slauer RD, Abburi N, Eckstein C, Shah S, et al. Catatonia in anti-NMDA receptor encephalitis: a case series and approach to improve outcomes with electroconvulsive therapy. BMJ Neurol Open. 2024;6(2):e000812. doi:10.1136/bmjno-2024-000812
23. Sahin A, Cicek M, Gonenc Cekic O, Gunaydin M, Aykut DS, Tatli O, et al. A retrospective analysis of cases with neuroleptic malignant syndrome and an evaluation of risk factors for mortality. Turk J Emerg Med. 2017;17(4):141–145. doi:10.1016/j.tjem.2017.10.001
24. Luccarelli J, Kalinich M, Rogers JP, Donovan AL, Smith FA, Beach SR, et al. Emergency department presentations for catatonia: a 2019–2021 National Emergency Department Sample study. J Acad Consult Liaison Psychiatry. 2025;66(5):380–388. doi:10.1016/j.jaclp.2025.08.006
25. Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care. 2016;24(1):97–103. doi:10.1007/s12028-015-0162-5
26. Guinart D, Misawa F, Rubio JM, Pereira J, de Filippis R, Gastaldon C, et al. A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand. 2021;144(4):329–341. doi:10.1111/acps.13359
27. Cronemeyer M, Schönfeldt-Lecuona C, Gahr M, Keller F, Sartorius A. Malignant catatonia: severity, treatment and outcome – a systematic case series analysis. World J Biol Psychiatry. 2022;23(1):78–86. doi:10.1080/15622975.2021.1925153
28. Cronemeyer M. Therapie und Outcome der Malignen Katatonie – eine systematische Fallserienanalyse [dissertation]. Ulm: Universität Ulm; 2021. Deutsche Nationalbibliothek
29. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–286. doi:10.7326/0003-4819-158-4-201302190-00009
30. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
31. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890. doi:10.1136/bmj.l6890


